Literature DB >> 21421818

Dysfunctional ryanodine receptor and cardiac hypertrophy: role of signaling molecules.

Naohiro Yamaguchi1, Asima Chakraborty, Daniel A Pasek, Jeffery D Molkentin, Gerhard Meissner.   

Abstract

Mice with three amino acid mutations in the calmodulin binding domain of type-2 ryanodine receptor ion channel (Ryr2(ADA/ADA) mice) have impaired intracellular Ca(2+) handling and cardiac hypertrophy with death at an early age. In this report, the role of signaling molecules implicated in cardiac hypertrophy of Ryr2(ADA/ADA) mice was investigated. Calcineurin A-β (CNA-β) and nuclear factor of activated T cell (NFAT) signaling were monitored in mice carrying either luciferase transgene driven by NFAT-dependent promoter or knockout of CNA-β. NFAT transcriptional activity in Ryr2(ADA/ADA) hearts was not markedly upregulated at embryonic day 16.5 compared with wild-type but significantly increased at postnatal days 1 and 10. Ablation of CNA-β extended the life span of Ryr2(ADA/ADA) mice and enhanced cardiac function without improving sarcoplasmic reticulum Ca(2+) handling or suppressing the expression of genes implicated in cardiac hypertrophy. Embryonic day 16.5 Ryr2(ADA/ADA) mice had normal heart weights with no major changes in Akt1 and class II histone deacetylase phosphorylation and myocyte enhancer factor-2 activity. In contrast, phosphorylation levels of Erk1/2, p90 ribosomal S6 kinases (p90RSKs), and GSK-3β were increased in hearts of embryonic day 16.5 homozygous mutant mice. The results indicate that an impaired calmodulin regulation of RyR2 was neither associated with an altered CNA-β/NFAT, class II histone deacetylase (HDAC)/MEF2, nor Akt signaling in embryonic day 16.5 hearts; rather increased Erk1/2 and p90RSK phosphorylation levels likely leading to reduced GSK-3β activity were found to precede development of cardiac hypertrophy in mice expressing dysfunctional ryanodine receptor ion channel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421818      PMCID: PMC3119098          DOI: 10.1152/ajpheart.00719.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  51 in total

Review 1.  Ryanodine receptor calcium release channels.

Authors:  Michael Fill; Julio A Copello
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

Review 2.  Transcriptional regulation by calcium, calcineurin, and NFAT.

Authors:  Patrick G Hogan; Lin Chen; Julie Nardone; Anjana Rao
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

3.  Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration.

Authors:  Hyung-Suk Kim; Gene Lee; Simon W M John; Nobuyo Maeda; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 4.  Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

Authors:  Stefan E Hardt; Junichi Sadoshima
Journal:  Circ Res       Date:  2002-05-31       Impact factor: 17.367

5.  Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.

Authors:  Christopher L Antos; Timothy A McKinsey; Norbert Frey; William Kutschke; John McAnally; John M Shelton; James A Richardson; Joseph A Hill; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

6.  Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Authors:  Benjamin J Wilkins; Yan-Shan Dai; Orlando F Bueno; Stephanie A Parsons; Jian Xu; David M Plank; Fred Jones; Thomas R Kimball; Jeffery D Molkentin
Journal:  Circ Res       Date:  2003-12-01       Impact factor: 17.367

7.  Developmental changes of Ca(2+) handling in mouse ventricular cells from early embryo to adulthood.

Authors:  Weiran Liu; Kenji Yasui; Tobias Opthof; Ryoji Ishiki; Jong-Kook Lee; Kaichiro Kamiya; Mitsuhiro Yokota; Itsuo Kodama
Journal:  Life Sci       Date:  2002-08-02       Impact factor: 5.037

8.  Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice.

Authors:  Stephanie A Parsons; Benjamin J Wilkins; Orlando F Bueno; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 9.  Cardiac hypertrophy: the good, the bad, and the ugly.

Authors:  N Frey; E N Olson
Journal:  Annu Rev Physiol       Date:  2003-01-09       Impact factor: 19.318

10.  Fetal and postnatal development of Ca2+ transients and Ca2+ sparks in rat cardiomyocytes.

Authors:  Sumihiko Seki; Masato Nagashima; Yoichi Yamada; Masaaki Tsutsuura; Takeshi Kobayashi; Akiyoshi Namiki; Noritsugu Tohse
Journal:  Cardiovasc Res       Date:  2003-06-01       Impact factor: 10.787

View more
  11 in total

1.  Calmodulin inhibition of human RyR2 channels requires phosphorylation of RyR2-S2808 or RyR2-S2814.

Authors:  Kafa Walweel; Nieves Gomez-Hurtado; Robyn T Rebbeck; Ye Wint Oo; Nicole A Beard; Peter Molenaar; Cris Dos Remedios; Dirk F van Helden; Razvan L Cornea; Björn C Knollmann; Derek R Laver
Journal:  J Mol Cell Cardiol       Date:  2019-03-27       Impact factor: 5.000

2.  Cardiac calcium signalling pathologies associated with defective calmodulin regulation of type 2 ryanodine receptor.

Authors:  Juan José Arnáiz-Cot; Brooke James Damon; Xiao-Hua Zhang; Lars Cleemann; Naohiro Yamaguchi; Gerhard Meissner; Martin Morad
Journal:  J Physiol       Date:  2013-07-08       Impact factor: 5.182

3.  Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2.

Authors:  Francisco J Alvarado; J Martijn Bos; Zhiguang Yuchi; Carmen R Valdivia; Jonathan J Hernández; Yan-Ting Zhao; Dawn S Henderlong; Yan Chen; Talia R Booher; Cherisse A Marcou; Filip Van Petegem; Michael J Ackerman; Héctor H Valdivia
Journal:  JCI Insight       Date:  2019-03-05

Review 4.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

5.  Cardiomyocyte ATP production, metabolic flexibility, and survival require calcium flux through cardiac ryanodine receptors in vivo.

Authors:  Michael J Bround; Rich Wambolt; Dan S Luciani; Jerzy E Kulpa; Brian Rodrigues; Roger W Brownsey; Michael F Allard; James D Johnson
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

6.  Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1.

Authors:  Naohiro Yamaguchi; Asima Chakraborty; Tai-Qin Huang; Le Xu; Angela C Gomez; Daniel A Pasek; Gerhard Meissner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-10       Impact factor: 4.733

7.  Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells.

Authors:  Jeffery D Molkentin
Journal:  Circ Res       Date:  2013-06-21       Impact factor: 17.367

8.  mTOR signaling in mice with dysfunctional cardiac ryanodine receptor ion channel.

Authors:  Tai-Qin Huang; Min-Xu Zou; Daniel A Pasek; Gerhard Meissner
Journal:  J Receptor Ligand Channel Res       Date:  2015

9.  Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor.

Authors:  Asima Chakraborty; Daniel A Pasek; Tai-Qin Huang; Angela C Gomez; Naohiro Yamaguchi; Mark E Anderson; Gerhard Meissner
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

10.  IL-6/STAT3 signaling in mice with dysfunctional type-2 ryanodine receptor.

Authors:  Tai-Qin Huang; Monte S Willis; Gerhard Meissner
Journal:  JAKSTAT       Date:  2016-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.